Bispecific Antibodies BCMA-CD3 Reduce Alloantibody Pre-Transplant
Summary
USPTO has published patent application US20260109772A1, filed October 9, 2023 under Application No. 19116305, covering methods for desensitizing solid organ transplant candidates using bispecific BCMA-CD3 antibodies. Eight named inventors (Singe, Norton, Harari, Limnander, Sleeman, Perlee, and Carpenter) disclose that the antibodies activate T cells via the CD3 complex in the presence of BCMA-expressing plasma cells, reducing anti-HLA alloantibody levels and calculated panel reactive antibody levels to facilitate transplantation and improve graft survival. CPC classifications include C07K 16/2878 (Fc receptor binding antibodies) and A61P 37/06 (immunological disorder therapeutics).
“The present invention provides methods for desensitizing patients in need of a solid organ transplant to anti-HLA antibodies using bispecific antibodies that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing plasma cells.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 229 changes logged to date.
What changed
USPTO published patent application US20260109772A1 disclosing bispecific antibodies targeting B-cell maturation antigen (BCMA) and CD3 for reducing alloantibody levels in solid organ transplant candidates. The invention leverages BCMA-expressing plasma cells to activate T cells via the CD3 complex, thereby reducing calculated panel reactive antibody (cPRA) levels and facilitating transplantation. The application names eight inventors and classifies the technology under C07K 16/2878 and A61P 37/06.
For biotech and pharmaceutical companies developing transplant desensitization therapies, this publication establishes a prior art date of October 9, 2023 for bispecific BCMA-CD3 antibody approaches in organ transplantation. Competitors pursuing similar plasma cell depletion strategies should review freedom-to-operate implications and assess whether their own patent filings predate this application's priority date.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods for Reducing Alloantibody Levels in Subjects in Need of Solid Organ Transplantation
Application US20260109772A1 Kind: A1 Apr 23, 2026
Inventors
Nikhil SINGE, Thomas D. NORTON, Olivier HARARI, Andre LIMNANDER, Matthew SLEEMAN, Lorah PERLEE, Stephen M. CARPENTER
Abstract
B-cell maturation antigen (BCMA) is expressed on plasma cells. The present invention provides methods for desensitizing patients in need of a solid organ transplant to anti-HLA antibodies using bispecific antibodies that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing plasma cells. In certain embodiments, the bispecific antibodies of the present invention reduce alloantibody levels and/or reduce calculated panel reactive antibody levels to facilitate solid organ transplantation and/or improve long term graft survival and/or function.
CPC Classifications
C07K 16/2878 A61P 37/06 C07K 16/2809 A61K 2039/505 C07K 2317/31
Filing Date
2023-10-09
Application No.
19116305
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.